Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
相关临床试验
6
6 进行中
药物批准
16
批准总数
监管机构
2
监管机构数
成立时间
1944
进行中（未招募）
5
83.3%
尚未招募
1
16.7%
- McKesson disclosed unauthorized access and data exfiltration from third-party applications in an SEC filing on August 28, 2026, after detecting the intrusion on August 25, 2026. - The extortion group ShinyHunters claims it stole roughly 284 million data records from McKesson's Snowflake and Salesforce environments, a figure representing database rows rather than confirmed unique patients. - Hackers say they used vishing calls to hijack Okta single sign-on accounts, then moved laterally into cloud systems over a four-day window between August 21 and August 25. - ShinyHunters demanded a ransom of $55,236,150 with a 72-hour deadline; McKesson reportedly never responded, and the company has declined to confirm how many individuals were affected.
- The first federal bellwether trial in the preterm infant formula multidistrict litigation, Inman v. Mead Johnson & Company, LLC, has proceeded to a jury in the Northern District of Illinois. - The case centers on allegations that Mead Johnson's cow's-milk-based Enfamil formula increased the risk of necrotizing enterocolitis (NEC) in a premature infant without adequate warning. - More than 825 lawsuits are consolidated in the federal MDL, with analysts estimating total potential liability ranging from roughly £400 million to £8 billion. - The outcome is expected to shape litigation against Mead Johnson and Abbott Laboratories, which together hold about 80% of the U.S. infant formula market.
- Wolfe Research upgraded Abbott Laboratories to Outperform from Peer Perform, setting a $130 target price on the healthcare and diagnostics company. - AbbVie was also upgraded to Outperform from Peer Perform at Wolfe Research, with a $300 target price objective. - The upgrades came as markets rallied broadly after consumer price index data landed in line with expectations at 3.4% year-over-year. - Stryker was cut to Peer Perform from Outperform at Wolfe Research, while Monopar Therapeutics was downgraded to Neutral from Overweight at Cantor Fitzgerald.
- A KFF Health News investigation reveals that the FDA has no record of any infant formula manufacturer ever reporting a death under the "reasonable possibility" standard since at least 2000. - Nearly 1,760 NEC lawsuits are pending against Abbott, with a Missouri appeals court upholding a $495 million judgment and calling Abbott's conduct "significantly reprehensible." - Internal company documents show Abbott scientists acknowledged in 2010 that bovine milk-based formulas are "believed to be the primary risk factor" for NEC in preterm infants. - The FDA's adverse event reporting requirements for infant formula are less demanding than those for drugs and medical devices, and formula death reports are not publicly disclosed.
- DexCom reported FY 2025 revenue of nearly $4.7 billion, a 15.6% increase, with net income of approximately $836.3 million and a net margin of 17.9%. - Insulet generated FY 2025 revenue of just over $2.7 billion, representing 30.9% growth, with net income of approximately $354.4 million and a net margin near 10.4%. - Both companies face competitive pressures from Abbott, Medtronic, and the rising popularity of GLP-1 drugs, while DexCom is also navigating a March 2025 FDA warning letter. - Insulet is favored for 2026 based on lower price-to-earnings and price-to-sales ratios, plus significant market upside with only 40-45% of type 1 and 5% of type 2 diabetes patients using automated treatment devices.
- Abbott Laboratories reported FY 2025 revenue of nearly $44.3 billion with a net margin of approximately 14.7%, while completing its acquisition of Exact Sciences to expand into cancer diagnostics. - Intuitive Surgical achieved FY 2025 revenue close to $10.1 billion, representing approximately 20.5% growth, with a net margin of nearly 28.4% and a debt-free balance sheet. - Abbott faces headwinds including product liability exposure, $20 billion in acquisition-related debt, and FDA regulatory scrutiny, while Intuitive Surgical confronts tariff impacts and increasing RAS market competition. - Both companies remain leaders in their respective niches, with Abbott offering diversified stability and dividends versus Intuitive Surgical's high-growth, razor-and-blades recurring revenue model.
- Abbott Laboratories is set to complete its $21 billion acquisition of Exact Sciences on Monday, adding established cancer screening and precision diagnostics assets including Cologuard and Oncotype DX to its portfolio. - Novartis announced a $2 billion upfront acquisition of early-stage PI3Kα inhibitor programs from Synnovation Therapeutics, targeting selective inhibition of mutated enzymes in cancer cells. - The contrasting deals highlight different strategic approaches in oncology, with Abbott focusing on established revenue-generating diagnostics platforms while Novartis pursues early-stage assets with differentiation potential. - Abbott expects the Exact Sciences transaction to contribute approximately $3 billion in incremental sales by 2026 within the estimated $60 billion US cancer screening and precision oncology diagnostics market.
- Novartis has confirmed plans to build a 46,000 square foot radioligand therapy manufacturing facility in Denton, Texas, as part of its $23 billion U.S. expansion strategy. - The facility will focus on manufacturing next-generation cancer treatments using radioligand therapy technology, which CEO Vas Narasimhan says has the potential to "revolutionize" cancer care. - Construction is expected to begin later this year and complete by 2028, creating at least 150 jobs in bioengineering, advanced manufacturing, quality and operations. - Denton City Council approved a $3.2 million incentive package including tax abatements and grants, with the project expected to generate nearly $5 million in revenue for the city over the next decade.
- Abbott Laboratories has initiated a voluntary correction for approximately 3 million FreeStyle Libre 3 and Libre 3 Plus continuous glucose monitoring sensors in the U.S. due to inaccurate low glucose readings. - The manufacturing defect has been linked to 736 severe adverse events globally, including seven deaths worldwide, though no deaths have been reported among American users. - The FDA has classified this as a "device correction" rather than a full recall, with Abbott offering free replacement sensors to affected users while fixing the underlying manufacturing issue. - Users can verify if their sensors are affected by checking serial numbers at www.FreeStyleCheck.com and requesting free replacements through Abbott's customer service.
- Abbott Laboratories announced plans to acquire Exact Sciences in a $21 billion deal, representing a major consolidation in the MedTech landscape. - The acquisition is designed to cement Abbott's leadership position in the rapidly growing cancer diagnostics market through innovative screening technologies. - The merger will immediately enhance Abbott's portfolio with non-invasive early-detection screening tools for cancer diagnosis. - The combined entity is positioned to accelerate the global availability of life-saving diagnostic solutions for patients worldwide.
